News

A study of approximately 1.2 million children found no evidence that early exposure to aluminum from vaccines increases the risk of autoimmune, allergic, or neurodevelopmental conditions.

Conversely, influenza vaccine was associated with increased COVID-19 severity and hospitalizations in patients with inflammatory rheumatic diseases.

Bristol Myers Squibb's deucravacitinib shows promise as a safe, effective treatment for active psoriatic arthritis, pending FDA approval by March 2026.

GLP-1 receptor agonists show promise in reducing pain, fatigue, and opioid use in fibromyalgia patients, suggesting a new therapeutic avenue.

A new study reveals that gout significantly affects hand function, with manual dexterity impairments nearly as severe as those seen in rheumatoid arthritis.

Findings suggest clinical risk factors involved in the development of psoriatic arthritis in children with psoriasis, including BMI and psoriasis location.

This study compared a combined pain neuroscience education and resistance training program with a different training program in women with fibromyalgia.

The AGILE and FORWARD studies found comparable efficacy and safety with shorter doses and higher dose, monthly doses, compared to the pivotal MIRROR trial.

TYK2 inhibition may offer a potentially better tolerated treatment option than JAK inhibitors for people with PsA.

New phase 3 trial data reveals Dapirolizumab pegol significantly reduces disease activity and fatigue in systemic lupus erythematosus patients, promising improved treatment outcomes.

A study reveals a significant link between poor oral health and increased migraines and body pain in women, highlighting implications for fibromyalgia management.

Explore groundbreaking FDA approvals and clinical trial advancements in rheumatology, offering new hope for patients with rare autoimmune diseases and chronic conditions.

This FDA News Month in Review provides a round-up of regulatory decisions from June 2025.

The rheumatology month in review emphasizes new research in RA burden, fibromyalgia treatment, and insights from the EULAR 2025 meeting.

An audio recap of the top 5 stories in healthcare news from the week of 06/16-06/22

Stay updated with the latest healthcare breakthroughs, including new phase 2/3 clinical trial data and an FDA approval, in this week's essential news roundup.

Presented at SDPA, the FOREMOST Trial showed apremilast reduces joint burden and improves function in early oligo PsA through week 48.

We spotlight 7 impactful regulatory decisions scheduled to occur during the second half of 2025.

With the approval, children ≥ 5 years of age with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration.

Stay updated with the latest healthcare breakthroughs, including FDA approvals, clinical trial data, and novel research, in this week's essential news roundup.

Populations most affected by RA are also growing younger and broader since 1990.

Recent research identifies 4 SNPs in the GCKR gene as significant genetic risk factors for gout, enhancing understanding of the disease's genetic basis.

New research highlights TNX-102 SL's potential to improve sleep and reduce pain in fibromyalgia, marking a significant advancement in treatment options.

A heightened risk of hyperuricemia and gout was observed with heavier, more frequent alcohol consumption, especially in males.

With the exception of duloxetine, milnacipran, and pregabalin, most therapies exhibited insignificant results in reducing pain.

New findings suggest Mu-Lympho-Marker could serve as a reliable biomarker for chronic pain in fibromyalgia, enhancing diagnosis and treatment strategies.

Depressive symptoms in the first 2 years after diagnosis were linked to lower odds of achieving remission in both RA and PsA.

Inebilizumab was approved by the FDA under the name Uplizna as the first and only treatment for adult patients with IgG4-RD in April 2025

New findings reveal upadacitinib's effectiveness in treating giant cell arteritis, highlighting reduced infection rates with shorter glucocorticoid tapering.

The findings are the latest from a series of trials seeking to decrease treatment burden for patients with uncontrolled gout.